Drug intelligence / Profile preview

[18F]PGM299

Development stage: Preclinical
Lead developer: Neurocrine Biosciences
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration: Intravenous

Overview

[18F]PGM299 is a radiopharmaceutical diagnostic agent developed for use in positron emission tomography (PET) imaging. It was initially developed by Neurocrine Biosciences. The compound is under investigation for applications in nervous system diseases, but as of now, its global highest R&D status is listed as pending. Specific details regarding its mechanism of action, molecular target, or primary clinical indication have not been disclosed in the available sources[1].

Targets

DAO (D-amino-acid oxidase)

Beyond the preview

Go deeper on [18F]PGM299.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]PGM299.